Versor Investments LP Has $373,000 Position in Tenet Healthcare Corporation $THC

Versor Investments LP cut its holdings in Tenet Healthcare Corporation (NYSE:THC) by 69.8% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 2,774 shares of the company’s stock after selling 6,426 shares during the quarter. Versor Investments LP’s holdings in Tenet Healthcare were worth $373,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. Affinity Investment Advisors LLC acquired a new position in shares of Tenet Healthcare in the 1st quarter valued at approximately $215,000. Raymond James Financial Inc. grew its position in shares of Tenet Healthcare by 17.6% in the 1st quarter. Raymond James Financial Inc. now owns 456,331 shares of the company’s stock valued at $61,377,000 after purchasing an additional 68,150 shares during the period. Tocqueville Asset Management L.P. acquired a new position in shares of Tenet Healthcare in the 1st quarter valued at approximately $271,000. Brandywine Global Investment Management LLC grew its position in shares of Tenet Healthcare by 84.5% in the 1st quarter. Brandywine Global Investment Management LLC now owns 95,329 shares of the company’s stock valued at $12,822,000 after purchasing an additional 43,648 shares during the period. Finally, Sector Gamma AS grew its position in shares of Tenet Healthcare by 95.5% in the 1st quarter. Sector Gamma AS now owns 43,000 shares of the company’s stock valued at $5,784,000 after purchasing an additional 21,000 shares during the period. 95.44% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director James L. Bierman sold 4,613 shares of the stock in a transaction on Thursday, May 29th. The stock was sold at an average price of $170.00, for a total value of $784,210.00. Following the sale, the director owned 35,271 shares in the company, valued at approximately $5,996,070. This represents a 11.57% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Paola M. Arbour sold 7,738 shares of the stock in a transaction on Thursday, June 5th. The shares were sold at an average price of $173.00, for a total value of $1,338,674.00. Following the completion of the sale, the executive vice president owned 20,110 shares in the company, valued at approximately $3,479,030. This trade represents a 27.79% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 32,873 shares of company stock worth $5,444,128 in the last quarter. Insiders own 0.81% of the company’s stock.

Tenet Healthcare Trading Up 2.3%

Shares of Tenet Healthcare stock opened at $182.07 on Thursday. Tenet Healthcare Corporation has a 12-month low of $109.82 and a 12-month high of $185.25. The stock has a market cap of $16.09 billion, a P/E ratio of 11.66, a P/E/G ratio of 0.76 and a beta of 1.52. The company has a quick ratio of 1.63, a current ratio of 1.71 and a debt-to-equity ratio of 2.39. The business’s 50 day moving average is $168.12 and its 200-day moving average is $149.13.

Tenet Healthcare (NYSE:THC) last announced its quarterly earnings data on Tuesday, July 22nd. The company reported $4.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.84 by $1.18. Tenet Healthcare had a return on equity of 24.69% and a net margin of 7.17%.The company had revenue of $5.27 billion for the quarter, compared to analysts’ expectations of $5.16 billion. During the same quarter in the prior year, the business posted $2.31 EPS. The business’s revenue was up 3.2% compared to the same quarter last year. Tenet Healthcare has set its FY 2025 guidance at 15.550-16.210 EPS. Equities research analysts predict that Tenet Healthcare Corporation will post 12.24 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have commented on the company. The Goldman Sachs Group boosted their target price on Tenet Healthcare from $134.00 to $154.00 and gave the company a “neutral” rating in a research note on Monday, May 5th. Morgan Stanley boosted their target price on Tenet Healthcare from $175.00 to $210.00 and gave the company an “overweight” rating in a research note on Monday, June 9th. Robert W. Baird cut their target price on Tenet Healthcare from $195.00 to $167.00 and set a “neutral” rating on the stock in a research note on Friday, July 25th. Mizuho boosted their target price on Tenet Healthcare from $184.00 to $194.00 and gave the company an “outperform” rating in a research note on Friday, July 11th. Finally, UBS Group boosted their target price on Tenet Healthcare from $230.00 to $238.00 and gave the company a “buy” rating in a research note on Wednesday, July 23rd. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, Tenet Healthcare presently has a consensus rating of “Moderate Buy” and a consensus price target of $191.88.

Tenet Healthcare Profile

Tenet Healthcare Corporation operates as a diversified healthcare services company in the United States. The company operates through two segments: Hospital Operations and Services, and Ambulatory Care. Its general hospitals offer acute care services, operating and recovery rooms, radiology and respiratory therapy services, clinical laboratories, and pharmacies.